SCHEMBL5238974

SCHEMBL5238974

CCCCOc1c(CO)n(CCC(C)C)c(=O)c2cc(Cl)c(Cl)cc12

nearest known ligand 0.36

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 8/20 0.36
MAPT P10636 2/20 0.33
HTT P42858 2/20 0.33
LMNA P02545 1/20 0.33
RXFP1 Q9HBX9 1/20 0.33
PDE2A O00408 2/20 0.33
NPSR1 Q6W5P4 2/20 0.32
PTGER4 P35408 1/20 0.32
PTGER2 P43116 1/20 0.32
MEN1 O00255 1/20 0.32
KMT2A Q03164 1/20 0.32
ADORA2A P29274 1/20 0.32
ADORA2B P29275 1/20 0.32
PDE1A P54750 1/20 0.32
PDE1B Q01064 1/20 0.32
PDE1C Q14123 1/20 0.32
GAA P10253 1/20 0.32
PGR P06401 1/20 0.32
CYP1A2 P05177 1/20 0.31
CYP3A4 P08684 1/20 0.31

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5238966 0.90 ALDH1A1 (0.37) ALDH1A1MAPTHTTLMNARXFP1
SCHEMBL5231965 0.90 DPP4 (0.37) ALDH1A1PGRPDE5ATHRATHRB
SCHEMBL7003974 0.89 DPP4 (0.39) ALDH1A1MAPTHTTLMNARXFP1
Hydrochloric Acid SCHEMBL5236063 0.88 DPP4 (0.39) ALDH1A1MAPTHTTLMNAPDE2A
SCHEMBL5238883 0.86 ALDH1A1 (0.47) ALDH1A1HTTNPSR1MEN1KMT2A
SCHEMBL5240015 0.86 PDE5A (0.35) ALDH1A1PGRPDE5ATHRATHRB
SCHEMBL5238212 0.86 RXFP1 (0.34) ALDH1A1MAPTRXFP1PTGER4PTGER2
SCHEMBL5232009 0.83 PLA2G2A (0.38) ALDH1A1MAPTHTTLMNARXFP1
SCHEMBL6106935 0.82 PTGER4 (0.32) ALDH1A1MAPTRXFP1NPSR1PTGER4
SCHEMBL5236317 0.82 THRB (0.35) ALDH1A1MAPTLMNANPSR1GAA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1355886-B1 FUSED HETEROCYCLIC COMPOUNDS TAKEDA PHARMACEUTICAL (JP) 2007-07-11 EP disclosed
US-7034039-B2 Fused heterocyclic compounds TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2006-04-25 US disclosed
US-20040082607-A1 Fused heterocyclic compounds TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2004-04-29 US disclosed
EP-1355886-A1 FUSED HETEROCYCLIC COMPOUNDS Takeda Chemical Industries, Ltd. (JP) 2003-10-29 EP disclosed
WO-2002062764-A1 FUSED HETEROCYCLIC COMPOUNDS TAKEDA CHEMICAL INDUSTRIES, LTD. (JP) 2002-08-15 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20040082607-A1 Fused heterocyclic compounds DPP7, DPP4, METAP1 ALDH1A1 387/4885MAPT 4855/4885HTT 3463/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.